ArticleCancer medicine2026
RELB Overexpression Induced by DNA Hypomethylation Contributes to Perioperative Immunotherapy Resistance in Resectable Esophageal Squamous Cell Carcinoma by Modulating the mregDC-Treg Axis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundPerioperative immunotherapy has significantly improved outcomes for patients with resectable esophageal squamous cell carcinoma (ESCC). Nevertheless, a substantial proportion of patients develop resistance to immunotherapy. This study aimed to identify biomarkers predictive of perioperative immunotherapy efficacy and elucidate the mechanisms underlying treatment resistance in non-responders with resectable ESCC.
methodsRELB expression in ESCC clinical samples and prognosis was first assessed using tissue microarrays. Bisulfite sequencing and methylation-specific PCR were employed to explore the mechanisms underlying RELB overexpression in ESCC. Subsequently, functional assays and western blot analysis were performed to evaluate the biological role of RELB in ESCC cells. Fifty-nine tissue samples were collected from patients who received perioperative immunotherapy for ESCC at our center and categorized into progressive disease (PD) and stable disease (SD) groups. Triple-label immunofluorescence staining, single-cell RNA sequencing, and bulk-RNA sequencing analyses were conducted to investigate the role of RELB in perioperative immunotherapy resistance.
resultsA correlation was revealed between perioperative immunotherapy resistance in ESCC and RELB expression. RELB overexpression in ESCC tissues, which is regulated by DNA hypomethylation, exhibited a significant positive correlation with poor prognosis and advanced tumor stage. RELB knockdown inhibited the migration and proliferation of Eca109 and KYSE450 cells while promoting their apoptosis. The elevated RELB expression in patients with ESCC increased perioperative immunotherapy resistance by driving the mature dendritic cells enriched in immunoregulatory molecules (mregDCs)-regulatory T cells (Tregs) axis for Treg recruitment and activation in the tumor microenvironment. Importantly, RELB was mainly enriched in and strongly correlated with the infiltration of mregDCs and Tregs. RELB+ mregDCs exhibited stronger interaction with Tregs and upregulation of IDO1 as well as activation of tryptophan metabolism.
conclusionsDNA hypomethylation-induced RELB overexpression promoted perioperative immunotherapy resistance in ESCC by driving the mregDC-Treg axis and is a potential predictive biomarker for perioperative immunotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.